U.S. Markets open in 9 hrs 20 mins

China Biologic Products Holdings, Inc. (CBPO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
113.49+0.05 (+0.04%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close113.44
Open113.62
Bid107.50 x 800
Ask113.74 x 1000
Day's Range113.01 - 113.99
52 Week Range97.91 - 119.44
Volume66,499
Avg. Volume87,936
Market Cap4.379B
Beta (5Y Monthly)0.62
PE Ratio (TTM)29.94
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • China Biologic Reports Financial Results for the Second Quarter of 2020
    PR Newswire

    China Biologic Reports Financial Results for the Second Quarter of 2020

    China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its unaudited financial results for the second quarter of 2020.

  • China Biologic Products to Report Second Quarter 2020 Financial Results
    PR Newswire

    China Biologic Products to Report Second Quarter 2020 Financial Results

    China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release its second quarter 2020 financial results on Monday, August 17, 2020 after the market closes.

  • China Biologic Provides Additional Comments on the Xinjiang Deyuan and Shuanglin Transaction
    PR Newswire

    China Biologic Provides Additional Comments on the Xinjiang Deyuan and Shuanglin Transaction

    China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today declared that the Company disagrees with the notice delivered by Xinjiang Deyuan Bioengineering Co., Ltd. ("Xinjiang Deyuan") to China Biologic, which attempts to terminate the cooperation between China Biologic and Xinjiang Deyuan, and urges Xinjiang Deyuan to cure its breaches and continue to perform its obligations under its cooperation agreement with China Biologic. In addition, the Company announced that, through the lawsuits it previously filed against Xinjiang Deyuan, the Company is seeking monetary claims totaling over RMB460 million and has obtained judicial freezing of certain shares of Xinjiang Deyuan and certain of its plasma collection stations. China Biologic will continue to take all necessary legal measures to vigorously protect its rights.